Advertisement
Review Article| Volume 44, ISSUE 1, P15-33, March 2023

The Lung Transplant Candidate, Indications, Timing, and Selection Criteria

  • Hannah Mannem
    Affiliations
    Division of Pulmonary and Critical Care Medicine, University of Virginia School of Medicine, PO Box 800546, Clinical Department Wing, 1 Hospital Drive, Charlottesville, VA 22908, USA
    Search for articles by this author
  • Meghan Aversa
    Affiliations
    Division of Respirology, Department of Medicine, University Health Network and University of Toronto, C. David Naylor Building, 6 Queen’s Park Crescent West, Third Floor, Toronto, ON M5S 3H2, Canada
    Search for articles by this author
  • Thomas Keller
    Affiliations
    Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington School of Medicine, 1959 Northeast Pacific Street, Campus Box 356522, Seattle, WA 98195, USA
    Search for articles by this author
  • Siddhartha G. Kapnadak
    Correspondence
    Corresponding author. Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington School of Medicine, 1959 Northeast Pacific Street, Campus Box 356122, Seattle, WA 98195.
    Affiliations
    Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington School of Medicine, 1959 Northeast Pacific Street, Campus Box 356522, Seattle, WA 98195, USA
    Search for articles by this author

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Chest Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chambers D.C.
        • Cherikh W.S.
        • Harhay M.O.
        • et al.
        The International thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: donor and recipient size match.
        J Heart Lung Transpl. 2019; 38: 1042-1055
        • Chambers D.C.
        • Perch M.
        • Zuckermann A.
        • et al.
        The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-eighth adult lung transplantation report - 2021; Focus on recipient characteristics.
        J Heart Lung Transpl. 2021; 40: 1060-1072
        • Valapour M.
        • Lehr C.J.
        • Skeans M.A.
        • et al.
        OPTN/SRTR 2020 annual data report: lung.
        Am J Transpl. 2022; 22: 438-518
        • Egan T.M.
        • Edwards L.B.
        Effect of the lung allocation score on lung transplantation in the United States.
        J Heart Lung Transpl. 2016; 35: 433-439
        • Benvenuto L.J.
        • Anderson M.R.
        • Aversa M.
        • et al.
        Geographic disparities in lung transplantation in the United States before and after the November 2017 allocation change.
        J Heart Lung Transpl. 2022; 41: 382-390
        • Mooney J.J.
        • Bhattacharya J.
        • Dhillon G.S.
        Effect of broader geographic sharing of donor lungs on lung transplant waitlist outcomes.
        J Heart Lung Transpl. 2019; 38: 136-144
        • Egan T.M.
        How should lungs be allocated for transplant?.
        Semin Respir Crit Care Med. 2018; 39: 126-137
        • Ramos K.J.
        • Quon B.S.
        • Psoter K.J.
        • et al.
        Predictors of non-referral of patients with cystic fibrosis for lung transplant evaluation in the United States.
        J Cyst Fibros. 2016; 15: 196-203
        • Tague L.K.
        • Witt C.A.
        • Byers D.E.
        • et al.
        Association between allosensitization and waiting list outcomes among adult lung transplant candidates in the United States.
        Ann Am Thorac Soc. 2019; 16: 846-852
        • Leard L.E.
        • Holm A.M.
        • Valapour M.
        • et al.
        Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation.
        J Heart Lung Transpl. 2021; 40: 1349-1379
        • Network OPaT
        Ethical principles in the allocation of human organs.
        (Available at:)
        • Ramos K.J.
        • Smith P.J.
        • McKone E.F.
        • et al.
        Lung transplant referral for individuals with cystic fibrosis: cystic Fibrosis Foundation consensus guidelines.
        J Cyst Fibros. 2019; 18: 321-333
        • Clausen E.S.
        • Frankel C.
        • Palmer S.M.
        • et al.
        Pre-transplant weight loss and clinical outcomes after lung transplantation.
        J Heart Lung Transpl. 2018; 37: 1443-1447
        • Li M.
        • Mathur S.
        • Chowdhury N.A.
        • et al.
        Pulmonary rehabilitation in lung transplant candidates.
        J Heart Lung Transpl. 2013; 32: 626-632
        • Wickerson L.
        • Rozenberg D.
        • Janaudis-Ferreira T.
        • et al.
        Physical rehabilitation for lung transplant candidates and recipients: an evidence-informed clinical approach.
        Worldj Transpl. 2016; 6: 517-531
        • Fernández Pérez E.R.
        • Daniels C.E.
        • Schroeder D.R.
        • et al.
        Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study.
        Chest. 2010; 137: 129-137
        • Flaherty K.R.
        • Toews G.B.
        • Travis W.D.
        • et al.
        Clinical significance of histological classification of idiopathic interstitial pneumonia.
        Eur Respir J. 2002; 19: 275-283
        • King Jr., T.E.
        • Bradford W.Z.
        • Castro-Bernardini S.
        • et al.
        A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
        N Engl J Med. 2014; 370: 2083-2092
        • Raghu G.
        • Wells A.U.
        • Nicholson A.G.
        • et al.
        Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria.
        Am J Respir Crit Care Med. 2017; 195: 78-85
        • Richeldi L.
        • du Bois R.M.
        • Raghu G.
        • et al.
        Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
        N Engl J Med. 2014; 370: 2071-2082
        • Nathan S.D.
        • Albera C.
        • Bradford W.Z.
        • et al.
        Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
        Lancet Respir Med. 2017; 5: 33-41
        • Lederer D.J.
        • Martinez F.J.
        Idiopathic pulmonary fibrosis.
        N Engl J Med. 2018; 378: 1811-1823
        • Kapnadak S.G.
        • Raghu G.
        Lung transplantation for interstitial lung disease.
        Eur Respir Rev. 2021; 30: 210017
        • du Bois R.M.
        • Weycker D.
        • Albera C.
        • et al.
        Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.
        Am J Respir Crit Care Med. 2011; 184: 459-466
        • Ley B.
        • Ryerson C.J.
        • Vittinghoff E.
        • et al.
        A multidimensional index and staging system for idiopathic pulmonary fibrosis.
        Ann Intern Med. 2012; 156: 684-691
        • Alhamad E.H.
        • Cal J.G.
        • Alrajhi N.N.
        • et al.
        Predictors of mortality in patients with interstitial lung disease-associated pulmonary hypertension.
        J Clin Med. 2020; 9: 3828
        • Chahal A.
        • Sharif R.
        • Watts J.
        • et al.
        Predicting outcome in idiopathic pulmonary fibrosis: addition of fibrotic score at thin-section ct of the chest to gender, age, and physiology score improves the prediction model.
        Radiol Cardiothorac Imaging. 2019; 1: e180029
        • Nasser M.
        • Larrieu S.
        • Si-Mohamed S.
        • et al.
        Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study).
        Eur Respir J. 2021; 57
        • Park J.H.
        • Kim D.S.
        • Park I.N.
        • et al.
        Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes.
        Am J Respir Crit Care Med. 2007; 175: 705-711
        • Cottin V.
        • Hirani N.A.
        • Hotchkin D.L.
        • et al.
        Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases.
        Eur Respir Rev. 2018; 27: 180076
        • Flaherty K.R.
        • Wells A.U.
        • Cottin V.
        • et al.
        Nintedanib in progressive fibrosing interstitial lung diseases.
        N Engl J Med. 2019; 381: 1718-1727
        • Maher T.M.
        • Corte T.J.
        • Fischer A.
        • et al.
        Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
        Lancet Respir Med. 2020; 8: 147-157
        • Distler O.
        • Highland K.B.
        • Gahlemann M.
        • et al.
        Nintedanib for systemic sclerosis-associated interstitial lung disease.
        N Engl J Med. 2019; 380: 2518-2528
        • Wells A.U.
        • Flaherty K.R.
        • Brown K.K.
        • et al.
        Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
        Lancet Respir Med. 2020; 8: 453-460
        • Raghu G.
        • Ley B.
        • Brown K.K.
        • et al.
        Risk factors for disease progression in idiopathic pulmonary fibrosis.
        Thorax. 2020; 75: 78-80
        • Snyder L.
        • Neely M.L.
        • Hellkamp A.S.
        • et al.
        Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry.
        Respir Res. 2019; 20: 105
        • Ratwani A.P.
        • Ahmad K.I.
        • Barnett S.D.
        • et al.
        Connective tissue disease-associated interstitial lung disease and outcomes after hospitalization: a cohort study.
        Respir Med. 2019; 154: 1-5
        • Khadawardi H.
        • Mura M.
        A simple dyspnoea scale as part of the assessment to predict outcome across chronic interstitial lung disease.
        Respirology. 2017; 22: 501-507
        • Amano M.
        • Izumi C.
        • Baba M.
        • et al.
        Progression of right ventricular dysfunction and predictors of mortality in patients with idiopathic interstitial pneumonias.
        J Cardiol. 2020; 75: 242-249
        • Hayes Jr., D.
        • Black S.M.
        • Tobias J.D.
        • et al.
        Influence of pulmonary hypertension on patients with idiopathic pulmonary fibrosis awaiting lung transplantation.
        Ann Thorac Surg. 2016; 101: 246-252
        • du Bois R.M.
        • Weycker D.
        • Albera C.
        • et al.
        Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.
        Am J Respir Crit Care Med. 2011; 183: 1231-1237
        • Celli B.R.
        • Cote C.G.
        • Marin J.M.
        • et al.
        The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.
        N Engl J Med. 2004; 350: 1005-1012
        • Bellou V.
        • Belbasis L.
        • Konstantinidis A.K.
        • et al.
        Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: systematic review and critical appraisal.
        BMJ. 2019; 367: l5358
        • Reed R.M.
        • Cabral H.J.
        • Dransfield M.T.
        • et al.
        Survival of lung transplant candidates with COPD: BODE score reconsidered.
        Chest. 2018; 153: 697-701
        • Pirard L.
        • Marchand E.
        Reassessing the BODE score as a criterion for listing COPD patients for lung transplantation.
        Int J Chron Obstruct Pulmon Dis. 2018; 13: 3963-3970
        • Thabut G.
        • Ravaud P.
        • Christie J.D.
        • et al.
        Determinants of the survival benefit of lung transplantation in patients with chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 2008; 177: 1156-1163
        • Oswald-Mammosser M.
        • Weitzenblum E.
        • Quoix E.
        • et al.
        Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure.
        Chest. 1995; 107: 1193-1198
        • LaFon D.C.
        • Bhatt S.P.
        • Labaki W.W.
        • et al.
        Pulmonary artery enlargement and mortality risk in moderate to severe COPD: results from COPDGene.
        Eur Respir J. 2020; 55: 1901812
        • Martinez F.J.
        • Foster G.
        • Curtis J.L.
        • et al.
        Predictors of mortality in patients with emphysema and severe airflow obstruction.
        Am J Respir Crit Care Med. 2006; 173: 1326-1334
        • Martinez F.J.
        • Han M.K.
        • Andrei A.C.
        • et al.
        Longitudinal change in the BODE index predicts mortality in severe emphysema.
        Am J Respir Crit Care Med. 2008; 178: 491-499
        • Seneff M.G.
        • Wagner D.P.
        • Wagner R.P.
        • et al.
        Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease.
        JAMA. 1995; 274: 1852-1857
        • Warwick M.
        • Fernando S.M.
        • Aaron S.D.
        • et al.
        Outcomes and resource utilization among patients admitted to the intensive care unit following acute exacerbation of chronic obstructive pulmonary disease.
        J Intensive Care Med. 2021; 36: 1091-1097
        • Heijerman H.G.M.
        • McKone E.F.
        • Downey D.G.
        • et al.
        Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
        Lancet. 2019; 394: 1940-1948
        • Barry P.J.
        • Mall M.A.
        • Álvarez A.
        • et al.
        Triple therapy for cystic fibrosis phe508del-gating and -residual function genotypes.
        N Engl J Med. 2021; 385: 815-825
        • Burgel P.R.
        • Durieu I.
        • Chiron R.
        • et al.
        Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease.
        Am J Respir Crit Care Med. 2021; 204: 64-73
        • Middleton P.G.
        • Mall M.A.
        • Dřevínek P.
        • et al.
        Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single phe508del allele.
        N Engl J Med. 2019; 381: 1809-1819
        • Flume P.A.
        • Biner R.F.
        • Downey D.G.
        • et al.
        Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
        Lancet Respir Med. 2021; 9: 733-746
        • McColley S.A.
        • Konstan M.W.
        • Ramsey B.W.
        • et al.
        Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV(1).
        J Cyst Fibros. 2019; 18: 94-101
        • Kapnadak S.G.
        • Dimango E.
        • Hadjiliadis D.
        • et al.
        Cystic fibrosis foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease.
        J Cyst Fibros. 2020; 19: 344-354
        • Kapnadak S.G.
        • Ramos K.J.
        • Dellon E.P.
        Enhancing care for individuals with advanced cystic fibrosis lung disease.
        Pediatr Pulmonol. 2021; 56: S69-S78
        • Kerem E.
        • Reisman J.
        • Corey M.
        • et al.
        Prediction of mortality in patients with cystic fibrosis.
        New Engl J Med. 1992; 326: 1187-1191
        • Milla C.E.
        • Warwick W.J.
        Risk of death in cystic fibrosis patients with severely compromised lung function.
        Chest. 1998; 113: 1230-1234
        • Ramos K.J.
        • Quon B.S.
        • Heltshe S.L.
        • et al.
        Heterogeneity in survival in adult patients with cystic fibrosis with FEV(1) < 30% of predicted in the United States.
        Chest. 2017; 151: 1320-1328
        • Hayes Jr., D.
        • Kirkby S.
        • Whitson B.A.
        • et al.
        Mortality risk and pulmonary function in adults with cystic fibrosis at time of wait listing for lung transplantation.
        Ann Thorac Surg. 2015; 100: 474-479
        • Lehr C.J.
        • Skeans M.
        • Dasenbrook E.
        • et al.
        Effect of including important clinical variables on accuracy of the lung allocation score for cystic fibrosis and chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 2019; 200: 1013-1021
        • Belkin R.A.
        • Henig N.R.
        • Singer L.G.
        • et al.
        Risk factors for death of patients with cystic fibrosis awaiting lung transplantation.
        Am J Respir Crit Care Med. 2006; 173: 659-666
        • de Boer K.
        • Vandemheen K.L.
        • Tullis E.
        • et al.
        Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.
        Thorax. 2011; 66: 680-685
        • Hayes Jr., D.
        • Tobias J.D.
        • Mansour H.M.
        • et al.
        Pulmonary hypertension in cystic fibrosis with advanced lung disease.
        Am J Respir Crit Care Med. 2014; 190: 898-905
        • Hayes Jr., D.
        • Tumin D.
        • Daniels C.J.
        • et al.
        Pulmonary artery pressure and benefit of lung transplantation in adult cystic fibrosis patients.
        Ann Thorac Surg. 2016; 101: 1104-1109
        • Martin C.
        • Chapron J.
        • Hubert D.
        • et al.
        Prognostic value of six minute walk test in cystic fibrosis adults.
        Respir Med. 2013; 107: 1881-1887
        • Flight W.G.
        • Barry P.J.
        • Bright-Thomas R.J.
        • et al.
        Outcomes following bronchial artery embolisation for haemoptysis in cystic fibrosis.
        Cardiovasc Intervent Radiol. 2017; 40: 1164-1168
        • Ramos K.J.
        • Hee Wai T.
        • Stephenson A.L.
        • et al.
        Development and internal validation of a prognostic model of 2-year death or lung transplant for cystic fibrosis.
        Chest. 2022; S0012-3692: 01049-01052
        • Chalmers J.D.
        • Goeminne P.
        • Aliberti S.
        • et al.
        The bronchiectasis severity index. An international derivation and validation study.
        Am J Respir Crit Care Med. 2014; 189: 576-585
        • Galiè N.
        • Humbert M.
        • Vachiery J.L.
        • et al.
        2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (ESC) and the European respiratory society (ERS): endorsed by: association for European paediatric and congenital Cardiology (AEPC), international society for heart and lung transplantation (ISHLT).
        Eur Heart J. 2016; 37: 67-119
        • Hoeper M.M.
        • Kramer T.
        • Pan Z.
        • et al.
        Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.
        Eur Respir J. 2017; 50: 1700740
        • Benza R.L.
        • Gomberg-Maitland M.
        • Elliott C.G.
        • et al.
        Predicting survival in patients with pulmonary arterial hypertension: the reveal risk score calculator 2.0 and comparison with ESC/ERS-Based Risk ASSESSMENT STrategies.
        Chest. 2019; 156: 323-337
        • Chakinala M.M.
        • Coyne D.W.
        • Benza R.L.
        • et al.
        Impact of declining renal function on outcomes in pulmonary arterial hypertension: a REVEAL registry analysis.
        J Heart Lung Transpl. 2018; 37: 696-705
        • van de Veerdonk M.C.
        • Kind T.
        • Marcus J.T.
        • et al.
        Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy.
        J Am Coll Cardiol. 2011; 58: 2511-2519
        • Badagliacca R.
        • Papa S.
        • Poscia R.
        • et al.
        The added value of cardiopulmonary exercise testing in the follow-up of pulmonary arterial hypertension.
        J Heart Lung Transpl. 2019; 38: 306-314
        • Galiè N.
        • Channick R.N.
        • Frantz R.P.
        • et al.
        Risk stratification and medical therapy of pulmonary arterial hypertension.
        Eur Respir J. 2019; 53: 1801889
        • Montani D.
        • O'Callaghan D.S.
        • Savale L.
        • et al.
        Pulmonary veno-occlusive disease: recent progress and current challenges.
        Respir Med. 2010; 104: S23-S32
        • Young A.
        • Vummidi D.
        • Visovatti S.
        • et al.
        Prevalence, treatment, and outcomes of coexistent pulmonary hypertension and interstitial lung disease in systemic sclerosis.
        Arthritis Rheumatol. 2019; 71: 1339-1349
        • Chen H.
        • Shiboski S.C.
        • Golden J.A.
        • et al.
        Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension.
        Am J Respir Crit Care Med. 2009; 180: 468-474
        • Gomberg-Maitland M.
        • Glassner-Kolmin C.
        • Watson S.
        • et al.
        Survival in pulmonary arterial hypertension patients awaiting lung transplantation.
        J Heart Lung Transpl. 2013; 32: 1179-1186
        • Savale L.
        • Le Pavec J.
        • Mercier O.
        • et al.
        Impact of high-priority allocation on lung and heart-lung transplantation for pulmonary hypertension.
        Ann Thorac Surg. 2017; 104: 404-411
        • Lyu D.M.
        • Goff R.R.
        • Chan K.M.
        The lung allocation score and its relevance.
        Semin Respir Crit Care Med. 2021; 42: 346-356
        • Demerouti E.
        • Karyofyllis P.
        • Manginas A.
        • et al.
        Improving survival in patients with pulmonary arterial hypertension: focus on intravenous epoprostenol.
        Am J Cardiovasc Drugs. 2019; 19: 99-105
        • Garcia M.V.F.
        • Souza R.
        • Costa E.L.V.
        • et al.
        Outcomes and prognostic factors of decompensated pulmonary hypertension in the intensive care unit.
        Respir Med. 2021; 190: 106685
        • Savale L.
        • Vuillard C.
        • Pichon J.
        • et al.
        Five-year survival after an acute episode of decompensated pulmonary arterial hypertension in the modern management era of right heart failure.
        Eur Respir J. 2021; 58: 2100466
        • Hoeper M.M.
        • Benza R.L.
        • Corris P.
        • et al.
        Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension.
        Eur Respir J. 2019; 53: 1801906
        • McCarthy C.
        • Gupta N.
        • Johnson S.R.
        • et al.
        Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management.
        Lancet Respir Med. 2021; 9: 1313-1327
        • McCormack F.X.
        • Inoue Y.
        • Moss J.
        • et al.
        Efficacy and safety of sirolimus in lymphangioleiomyomatosis.
        N Engl J Med. 2011; 364: 1595-1606
        • Yao J.
        • Taveira-DaSilva A.M.
        • Jones A.M.
        • et al.
        Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.
        Am J Respir Crit Care Med. 2014; 190: 1273-1282
        • Gupta N.
        • Lee H.S.
        • Ryu J.H.
        • et al.
        The NHLBI LAM registry: prognostic physiologic and radiologic biomarkers emerge from a 15-year prospective longitudinal analysis.
        Chest. 2019; 155: 288-296
        • Oprescu N.
        • McCormack F.X.
        • Byrnes S.
        • et al.
        Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry.
        Lung. 2013; 191: 35-42
        • Kirkil G.
        • Lower E.E.
        • Baughman R.P.
        Predictors of mortality in pulmonary sarcoidosis.
        Chest. 2018; 153: 105-113
        • Meyer K.C.
        Lung transplantation for pulmonary sarcoidosis.
        Sarcoidosis Vasc Diffuse Lung Dis. 2019; 36: 92-107
        • Le Pavec J.
        • Valeyre D.
        • Gazengel P.
        • et al.
        Lung transplantation for sarcoidosis: outcome and prognostic factors.
        Eur Respir J. 2021; 58: 2003358
        • Akagi T.
        • Matsumoto T.
        • Harada T.
        • et al.
        Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis.
        Respir Med. 2009; 103: 1209-1215
        • Yoon H.Y.
        • Kim T.H.
        • Seo J.B.
        • et al.
        Effects of emphysema on physiological and prognostic characteristics of lung function in idiopathic pulmonary fibrosis.
        Respirology. 2019; 24: 55-62
        • Ranieri V.M.
        • Rubenfeld G.D.
        • Thompson B.T.
        • et al.
        Acute respiratory distress syndrome: the Berlin Definition.
        JAMA. 2012; 307: 2526-2533
        • Chang Y.
        • Lee S.O.
        • Shim T.S.
        • et al.
        Lung transplantation as a therapeutic option in acute respiratory distress syndrome.
        Transplantation. 2018; 102: 829-837
        • Kon Z.N.
        • Dahi S.
        • Evans C.F.
        • et al.
        Long-term venovenous extracorporeal membrane oxygenation support for acute respiratory distress syndrome.
        Ann Thorac Surg. 2015; 100: 2059-2063
        • Combes A.
        • Hajage D.
        • Capellier G.
        • et al.
        Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome.
        N Engl J Med. 2018; 378: 1965-1975
        • Novick R.J.
        • Stitt L.W.
        • Al-Kattan K.
        • et al.
        Pulmonary retransplantation: predictors of graft function and survival in 230 patients. Pulmonary Retransplant Registry.
        Ann Thorac Surg. 1998; 65: 227-234
        • Kawut S.M.
        • Lederer D.J.
        • Keshavjee S.
        • et al.
        Outcomes after lung retransplantation in the modern era.
        Am J Respir Crit Care Med. 2008; 177: 114-120
        • Verleden S.E.
        • Todd J.L.
        • Sato M.
        • et al.
        Impact of CLAD phenotype on survival after lung retransplantation: a multicenter study.
        Am J Transpl. 2015; 15: 2223-2230
        • Hall D.J.
        • Belli E.V.
        • Gregg J.A.
        • et al.
        Two decades of lung retransplantation: a single-center experience.
        Ann Thorac Surg. 2017; 103: 1076-1083
        • Wallinder A.
        • Danielsson C.
        • Magnusson J.
        • et al.
        Outcomes and long-term survival after pulmonary retransplantation: a single-center experience.
        Ann Thorac Surg. 2019; 108: 1037-1044
        • Young J.S.
        • Coppolino A.
        Esophageal disease in lung transplant patients.
        Ann Transl Med. 2021; 9: 900
        • Davis Jr., R.D.
        • Lau C.L.
        • Eubanks S.
        • et al.
        Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation.
        J Thorac Cardiovasc Surg. 2003; 125: 533-542
        • Hartwig M.G.
        • Anderson D.J.
        • Onaitis M.W.
        • et al.
        Fundoplication after lung transplantation prevents the allograft dysfunction associated with reflux.
        Ann Thorac Surg. 2011; 92 (discussion; 468-469): 462-468
        • Hoppo T.
        • Jarido V.
        • Pennathur A.
        • et al.
        Antireflux surgery preserves lung function in patients with gastroesophageal reflux disease and end-stage lung disease before and after lung transplantation.
        Arch Surg. 2011; 146: 1041-1047
        • ASTS/AST/ISHLT
        Joint statement about COVID-19 vaccination in organ transplant candidates and recipients.
        (Available at:)
        • Rosenberger E.M.
        • Dew M.A.
        • DiMartini A.F.
        • et al.
        Psychosocial issues facing lung transplant candidates, recipients and family caregivers.
        Thorac Surg Clin. 2012; 22: 517-529
        • Smith P.J.
        • Blumenthal J.A.
        • Snyder L.D.
        • et al.
        Depressive symptoms and early mortality following lung transplantation: a pilot study.
        Clin Transpl. 2017; 31: e12874
        • Smith P.J.
        • Blumenthal J.A.
        • Trulock E.P.
        • et al.
        Psychosocial predictors of mortality following lung transplantation.
        Am J Transpl. 2016; 16: 271-277
        • Smith P.J.
        • Snyder L.D.
        • Palmer S.M.
        • et al.
        Depression, social support, and clinical outcomes following lung transplantation: a single-center cohort study.
        Transpl Int. 2018; 31: 495-502
        • Dobbels F.
        • Verleden G.
        • Dupont L.
        • et al.
        To transplant or not? The importance of psychosocial and behavioural factors before lung transplantation.
        Chron Respir Dis. 2006; 3: 39-47
        • Pradère P.
        • Tudorache I.
        • Magnusson J.
        • et al.
        Lung transplantation for scleroderma lung disease: an international, multicenter, observational cohort study.
        J Heart Lung Transpl. 2018; 37: 903-911
        • Chan E.Y.
        • Goodarzi A.
        • Sinha N.
        • et al.
        Long-term survival in bilateral lung transplantation for scleroderma-related lung disease.
        Ann Thorac Surg. 2018; 105: 893-900
        • Jennerich A.L.
        • Pryor J.B.
        • Wai T.Y.H.
        • et al.
        Low body mass index as a barrier to lung transplant in cystic fibrosis.
        J Cyst Fibros. 2022; 21: 475-481
        • Ramos K.J.
        • Kapnadak S.G.
        • Bradford M.C.
        • et al.
        Underweight patients with cystic fibrosis have acceptable survival following lung transplantation: a united Network for organ sharing registry study.
        Chest. 2020; 157: 898-906
        • Hayanga A.J.
        • Aboagye J.K.
        • Hayanga H.E.
        • et al.
        Contemporary analysis of early outcomes after lung transplantation in the elderly using a national registry.
        J Heart Lung Transpl. 2015; 34: 182-188
        • Perez A.A.
        • Singer J.P.
        • Schwartz B.S.
        • et al.
        Management and clinical outcomes after lung transplantation in patients with pre-transplant Mycobacterium abscessus infection: a single center experience.
        Transpl Infect Dis. 2019; 21: e13084
        • Raats D.
        • Lorent N.
        • Saegeman V.
        • et al.
        Successful lung transplantation for chronic Mycobacterium abscessus infection in advanced cystic fibrosis, a case series.
        Transpl Infect Dis. 2019; 21: e13046
        • Al-Adra D.P.
        • Hammel L.
        • Roberts J.
        • et al.
        Pretransplant solid organ malignancy and organ transplant candidacy: a consensus expert opinion statement.
        Am J Transpl. 2021; 21: 460-474
        • Al-Adra D.P.
        • Hammel L.
        • Roberts J.
        • et al.
        Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: a consensus expert opinion statement.
        Am J Transpl. 2021; 21: 475-483
        • Lanken P.N.
        • Terry P.B.
        • Delisser H.M.
        • et al.
        An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses.
        Am J Respir Crit Care Med. 2008; 177: 912-927
        • Ruggiero R.
        • Reinke L.F.
        Palliative care in advanced lung diseases: a void that needs filling.
        Ann Am Thorac Soc. 2018; 15: 1265-1268
        • Halpin D.M.G.
        Palliative care for people with COPD: effective but underused.
        Eur Respir J. 2018; 51: 1702645
        • Hayanga A.J.
        • Aboagye J.
        • Esper S.
        • et al.
        Extracorporeal membrane oxygenation as a bridge to lung transplantation in the United States: an evolving strategy in the management of rapidly advancing pulmonary disease.
        J Thorac Cardiovasc Surg. 2015; 149: 291-296
        • Benazzo A.
        • Schwarz S.
        • Frommlet F.
        • et al.
        Twenty-year experience with extracorporeal life support as bridge to lung transplantation.
        J Thorac Cardiovasc Surg. 2019; 157 (e2510): 2515-2525
        • Hoetzenecker K.
        • Donahoe L.
        • Yeung J.C.
        • et al.
        Extracorporeal life support as a bridge to lung transplantation-experience of a high-volume transplant center.
        J Thorac Cardiovasc Surg. 2018; 155: 1316-1328.e1311
        • Fuehner T.
        • Kuehn C.
        • Hadem J.
        • et al.
        Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation.
        Am J Respir Crit Care Med. 2012; 185: 763-768
        • Lafarge M.
        • Mordant P.
        • Thabut G.
        • et al.
        Experience of extracorporeal membrane oxygenation as a bridge to lung transplantation in France.
        J Heart Lung Transpl. 2013; 32: 905-913
        • Biscotti M.
        • Gannon W.D.
        • Agerstrand C.
        • et al.
        Awake extracorporeal membrane oxygenation as bridge to lung transplantation: a 9-year experience.
        Ann Thorac Surg. 2017; 104: 412-419
        • Hayanga J.W.
        • Lira A.
        • Aboagye J.K.
        • et al.
        Extracorporeal membrane oxygenation as a bridge to lung transplantation: what lessons might we learn from volume and expertise?.
        Interact Cardiovasc Thorac Surg. 2016; 22: 406-410
        • Mattar A.
        • Chatterjee S.
        • Loor G.
        Bridging to lung transplantation.
        Crit Care Clin. 2019; 35: 11-25
        • Aversa M.
        Approaches to the management of sensitized lung transplant candidates: findings from an international survey.
        J Heart Lung Transpl. 2020; 39: S315
        • Abrams D.
        • Javidfar J.
        • Farrand E.
        • et al.
        Early mobilization of patients receiving extracorporeal membrane oxygenation: a retrospective cohort study.
        Crit Care. 2014; 18: R38
        • Georges G.
        • Kalavrouziotis D.
        • Mohammadi S.
        Commentary: walking wounded: role of ambulatory femoral venovenous extracorporeal membrane oxygenation.
        JTCVS Tech. 2021; 9: 204-205
        • Pasrija C.
        • Mackowick K.M.
        • Raithel M.
        • et al.
        Ambulation with femoral arterial cannulation can Be safely performed on venoarterial extracorporeal membrane oxygenation.
        Ann Thorac Surg. 2019; 107: 1389-1394
        • Tang A.
        • Thuita L.
        • Siddiqui H.U.
        • et al.
        Urgently listed lung transplant patients have outcomes similar to those of electively listed patients.
        J Thorac Cardiovasc Surg. 2020; S0022-5223: 30997-31001
        • Gan C.T.
        • Hoek R.A.S.
        • van der Bij W.
        • et al.
        Long-term outcome and bridging success of patients evaluated and bridged to lung transplantation on the ICU.
        J Heart Lung Transpl. 2022; 41: 589-598
        • Bharat A.
        • Querrey M.
        • Markov N.S.
        • et al.
        Lung transplantation for patients with severe COVID-19.
        Sci Transl Med. 2020; 12: eabe4282
        • Bush E.L.
        • Krishnan A.
        • Chidi A.P.
        • et al.
        The effect of the cystic fibrosis care center on outcomes after lung transplantation for cystic fibrosis.
        J Heart Lung Transpl. 2022; 41: 300-307